Edward Wirth Sells 3,415 Shares of Asterias Biotherapeutics Inc (AST) Stock
Asterias Biotherapeutics Inc (NYSEMKT:AST) insider Edward Wirth sold 3,415 shares of the stock in a transaction that occurred on Thursday, October 6th. The stock was sold at an average price of $4.12, for a total value of $14,069.80. The sale was disclosed in a filing with the SEC, which is available at this link.
Edward Wirth also recently made the following trade(s):
- On Friday, September 9th, Edward Wirth sold 14,760 shares of Asterias Biotherapeutics stock. The stock was sold at an average price of $3.52, for a total value of $51,955.20.
Asterias Biotherapeutics (NYSEMKT:AST) last announced its earnings results on Monday, August 15th. The company reported ($0.12) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.07. The company had revenue of $1.53 million for the quarter, compared to analyst estimates of $1.14 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/12/edward-wirth-sells-3415-shares-of-asterias-biotherapeutics-inc-ast-stock.html
Hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Fund Advisors raised its position in Asterias Biotherapeutics by 114.4% in the second quarter. BlackRock Fund Advisors now owns 586,720 shares of the company’s stock valued at $1,408,000 after buying an additional 313,067 shares during the period. Sabby Management LLC acquired a new position in Asterias Biotherapeutics during the second quarter valued at $741,000. State Street Corp raised its position in Asterias Biotherapeutics by 5.5% in the first quarter. State Street Corp now owns 96,218 shares of the company’s stock valued at $452,000 after buying an additional 5,000 shares during the period. BlackRock Investment Management LLC raised its position in Asterias Biotherapeutics by 100.7% in the second quarter. BlackRock Investment Management LLC now owns 73,307 shares of the company’s stock valued at $176,000 after buying an additional 36,782 shares during the period. Finally, Bank of New York Mellon Corp raised its position in Asterias Biotherapeutics by 55.7% in the second quarter. Bank of New York Mellon Corp now owns 54,406 shares of the company’s stock valued at $131,000 after buying an additional 19,469 shares during the period.
A number of equities research analysts recently issued reports on the company. Zacks Investment Research raised Asterias Biotherapeutics from a “hold” rating to a “buy” rating and set a $3.25 price target on the stock in a research report on Thursday, August 18th. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Asterias Biotherapeutics in a research report on Sunday, September 11th. Finally, FBR & Co reissued a “buy” rating on shares of Asterias Biotherapeutics in a research report on Wednesday, August 31st. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $7.75.
About Asterias Biotherapeutics
Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.
Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.